anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention discloses a tropaeolum health care tea and a preparation method thereof. The tropaeolum health care tea is prepared from the raw materials by the following weight ratio of 20 to 40% of tropaeolum, 8 to 15% of peony, 10 to 20% of baical skullcap root, 8 to 15% of rose flower, 15 to 30% of astragalus hoangtchy, 9 to 25% of green tea core or scented tea, and the baical skullcap root and the astragalus hoangtchy are steamed for 1 to 2 minutes in a steam pot at the temperature of 90 DEG C to 100 DEG C, aired out of the steam pot, and crumbled into 30 to 40 meshes. The tropaeolum, the peony and the rose flower are frozen according to a compounding ratio by weight, and the freezing temperature is from 18 DEG C below 0 to 20 DEG C below 0. The tropaeolum, the peony and the rose flower are crumbled into 30 to 40 meshes after 30 minutes. A green tea core or the scented tea is crumbled into 30 to 40 meshes according to the compounding ratio by weight. After being crumbled, the materials are stirred, mixed, and aired in a mild wind, and the water content is less than 5%. The materials are sterilized by infrared, and the materials are subpackaged by an automatic tea packaging machine after quality testing. Each package is 2g in weight, and then 40 packages each of which weighs 2g are packaged in boxes. The present invention widens the production area of tea seeds and tea. The tropaeolum health care tea has the advantages of cold resistance in winters, heat avoidance in summers, beautification, no furunculosis, no malignant boil, low cost and easy popularization, and has the functions for preventing and treating a plurality of diseases.
BACKGROUND AND OBJECTIVE: Many recent studies in virtual reality (VR) have managed the sense of Presence to assess the suitability of their designs, mainly when focused on learning goals that require high user engagement, such as in serious games for psychomotor training. However, the place and plausibility illusions needed to promote Presence are achieved by combining different VR-based design cues, and their individual contribution to preserving the Presence's engagement/involvement component is still unclear. This article explored the single effect of breaking the sense of Presence per VR factor, i.e., removing VR cues related to Social Presence (human interactions), Self-Presence (embodiment), and Physical Presence (Scenario realism).
METHODS: Thirty-three participants were asked to play an immersive VR simulation of an arcade game three times by experiencing a stepped Break of Illusion in one of the VR factors, i.e., while two factors were kept high, the remaining one was reduced to a low and null (hypothetical) level. The game difficulty was fixed after assessing each person's skills.
RESULTS: Results showed that psychophysiology indicators (heart rate and skin conductance) were not affected by the level of illusion, whereas exercise intensity was significantly higher with low body and social presence-based conditions. Moreover, skin conductance was lower in the Social-presence group, which suggests that perspiration is only affected by breaks in realism (scenario and body representations). Based on the obtained evidence, we proposed some guidelines for adapting the design of immersive virtual environments through Breaks in Presence, mainly by changing the realism of the scenario and body representation depending on the skin conductance or the interaction with virtual humans depending on exercise intensity.
Busulfan/VP16/Cyclophosphamide is an alternative conditioning arm that may optionally be used for HSCT with MSD/MD and MMD graft in patients aged 0-24 months. Patients undergoing MD HSCT will also receive ATG Thymo- or Grafalon.
Recent studies have demonstrated that there are cortical direct current (DC) changes that accompany sleep onset and transitions between sleep states in a stereotyped manner. In these studies it was determined that negative potential shifts occurred prior to and at the transition from wakefulness to sleep and at transitions between Rapid Eye Movement sleep (REM) sleep, and Non-Rapid Eye Movement (NREM) sleep. In a subset of experiments it was demonstrated that the same DC potential shifts occur during the transition from wake to sleep in an afternoon nap. The recorded DC potential shifts occurred predominantly in the pre-frontal cortex (F3, F4), with spread into central areas. No current literature exists that explores whether tDCS could be used to modulate cortical activity prior to sleep, resulting in either increased or decreased sleep propensity.

The application of focal, non-invasive brain stimulation has already led to novel and effective treatments for neuropsychiatric disease with minimal side effects (Most well studied in depression and repetitive Transcranial Magnetic Stimulation or, rTMS). Should the application of tDCS modulate sleep propensity it would represent a novel study paradigm with the potential to lead to a completely novel treatment for sleep disturbance. With this small pilot study, we propose taking the first step in exploring the utility of tDCS in modulating sleep propensity. We propose to recruit 15 healthy non-treatment seeking participants from the community and expose them to three total nap conditions in a randomized counter balanced fashion, with 10 minutes of either, Anodal, Cathodal, or Sham tDCS stimulation occurring prior to each nap opportunity.
The invention comprises the tetrahydrate, hydrobromide, hydriodide, nitrate, sulphate, sulphanilate and naphthalene-b -sulphonate of cocarboxylase (aneurin pyrophosphoric ester), and the preparation thereof and of other salts of cocarboxylase by dissolving in water the mixture of orthophosphoric acid and various phosphoric acid esters of aneurin obtained by phosphorylation of aneurin, obtaining from this solution with the aid of one or more suitable ion exchange resins an aqueous solution of cocarboxylase tetrahydrate, isolating this compound in crystalline form therefrom by removal of the solvent water or preferably by addition of a precipitating agent (e.g. a lower alcohol or acetone) and, if desired, converting the crystalline tetrahydrate into a salt of cocarboxylase by treatment with an acid. The solution from which the cocarboxylase tetrahydrate is crystallized may be obtained by adding a precipitating agent to the aqueous solution of the phosphorylation mixture, redissolving and reprecipating two or three times, if desired, and dissolving the resulting syrup in a little water, and then: (a) passing the solution over a weakly basic anion exchange resin and separating the portion off the eluate running off at pH5.5 to 1; or (b) passing the original solution or that obtained according to (a) over a strongly basic anion exchange resin and separating the portion of the eluate running off at pH 5.5 to 1; or (c) passing the solution obtained according to (a) over a cation exchange resin (which retains aneurin orthophosphoric ester and allows a purified solution of cocarboxylase tetrahydrate to run through.  Aneurin orthophosphoric ester may be subsequently eluted with 10% hydrochloric acid, and is also obtainable as a by-product in (a) and (b)).  Alternatively, an aqueous solution of a cocarboxylase salt, especially one still containing impurities, may be treated with an ion exchange resin, preferably an anion exchange resin.  Specifications 687,673, 687,674 and 793,753 are referred to.
Using the twin study approach, the investigators demonstrated that time with middle ear effusion (MEE), number of episodes of MEE and numbers of episodes of acute otitis media (AOM) have a strong genetic component. The point estimate of heritability of time with MEE was 0.73. While there is significant evidence that susceptibility to recurrent/persistent OM is largely genetically determined, the specific genes which confer susceptibility are unknown. The overall research strategy to identify genes underlying OM is to apply a three-stage study design that will allow the investigators to balance cost efficiency with statistical power. Five hundred evaluable pairs of siblings with a history of tympanostomy tube insertion (affected), their parent(s) and available non-affected full siblings will be recruited. A blood sample will be obtained from each subject for genotyping.
Cervicobrachial Neuralgia is characterized by pain and discomfort in the arm, specifically in conjunction with pain in the cervical spine. It has been observed that a significant number of patients seeking therapy for cervical spine diseases are affected by this type of pain. When an illness is chronic, it has a tendency to manifest as a persistent or recurring issue that has a negative impact on an individual's mental and physical well-being.

It is a randomized clinical trial. 30 patients fulfilling the inclusion and exclusion criteria will be recruited by non-probability convenience sampling and then randomly divided in two groups using lottery method. Group A will receive the strengthening and kinesiotherapy exercises along with Brugger's relief position training with 10 minutes per session and cervical lateral glide mobilization, 3 times a week. And the group B will receive the cervical lateral glide mobilization. Pain levels will be measured using a visual analogue scale and goniometer will be used to measure neck ranges.The data will be analyzed by using SPSS version25.
This is an open-label, multicenter, dose-escalation and expansion, first-in-human study in participants of CML with T315I mutation or without T315I mutation in chronic phase/accelerate phase(CP/AP). This study will consist of two parts: A part 1 dose escalation stage and a part 2 dose expansion stage. The objectives of this study are to evaluate the safety, tolerability, PK and preliminary anti-CML activity, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or maximum applicable dose (MAD) of HS-10382. Participants with CML-CP/AP are eligible for dose escalation study if they had resistance to or unacceptable side effect from BCR-ABL1 TKIs. After determination of the MTD or the MAD for CML patients, dose expansion will be undertaken to further evaluate the efficacy and safety of HS-10382 in patients with CML-CP. All patients will be carefully followed for adverse events during the study treatment and for 28 days after the last dose of study drug. Subjects of this study will be permitted to continue therapy with assessments for progression if the product is well tolerated and the subject has stable disease or better.
Vitamins of the B12 group are eluted from montmorillonite adsorbates containing such vitamins by means of aqueous solutions which contain one or more sulphur-containing compounds of the group consisting of sulphite ion yielding compounds, thiosemicarbazide and thioglycollic acid.  The compounds forming sulphite ions in aqueous solution are constituted by sulphurous acid (SO2), sulphites, bisulphites, dithionites or pyrosulphites and may form 0.08 to 0.4 per cent w/v. of the elution agent.  Thiosemicarbazide or thioglycollic acid may be used in the proportion 0.1 to 0.2 per cent w/v. of the elution agent. Initially the pH value of the elution agent may be adjusted to 7 to 9 by means of sodium hydroxide and maintained at this value by means of buffers such as sodium bicarbonate or secondary sodium phosphate. The eluate thus obtained from the montmorillonite adsorbate may be treated with active charcoal and the adsorbate thus obtained again eluted.
The first session will be right after the pre-test, the second session will be 15 days after the first session, and the last session will be 15 days after the second session. After the training is over, a total of 40 messages will be sent to the students in the initiative group, taking into account the factors that affect, strengthen and activate the main communication via the WhatsApp program.
Each year more than 500,000 cardiac surgeries are performed in the United States of America (USA) alone. Acute kidney injury ( AK) I is a common complication following cardiac surgery and is associated with poor patient outcomes and increased healthcare costs. Therefore, there is an urgent need to identify medical interventions and treatments that prevent AKI or mitigate its severity when it occurs after cardiac surgery.

One of the main causes of AKI following cardiac surgery involves renal hypoperfusion/ischemia and reperfusion injury. Hypoxia-inducible factors (HIFs) are key transcription factors responsible for tissue adaptation to low oxygen, which orchestrate the expression of a wide variety of genes including a set of micro-ribonucleic acid (microRNAs). MicroRNAs are endogenous single-stranded noncoding miRNAs of nucleotides that participate in physiological and pathological functions via regulating post-transcription of target genes. During ischemic injury, hypoxia upregulates endothelial MicroRNAs that has the potential in renal protection through vascular integrity and regeneration. Additionally, microRNAs exert protective effects via decreasing apoptosis and promoting tubular cell proliferation during ischemic AKI.

Moreover, decreased serum levels of MicroRNAs are highly correlated with AKI severity in the intensive care unit (ICU) patients. Our preliminary study identified ATP4A as the downstream target gene of MicroRNAs in the kidney. Adenosine triphosphate (ATP)4A (catalytic α subunit of H+/K+ ATPase) is located in intercalated cells in the distal tubules and cortical collecting ducts, which regulates urine acidification through secretion of hydrogen and reabsorption of potassium from urine. Proton pump inhibitors (PPIs) block the ATP hydrolysis of the H+/K+ ATPase via binding its active site of ATP4A and further enhance this endogenous kidney protection pathway. Despite robust animal model data, randomized controlled trial aiming to test the effectiveness of PPI in post-cardiac surgery AKI prevention is lacking. If proven to be effective, our studies could be easily implemented in clinical practice and serve as an effective treatment for perioperative AKI.
OBJECTIVES: Blood gas analysis, including parameters like lactate and base excess (BE), is crucial in emergency medicine but less commonly utilized prehospital. This study aims to elucidate the relationship between lactate and BE in various emergencies in a prehospital setting and their prognostic implications.
METHODS: We conducted a retrospective analysis of prehospital emergency patients in Graz, Austria, from October 2015 to November 2020. Our primary aim was to assess the association between BE and lactate. This was assessed using Spearman's rank correlation and fitting a multiple linear regression model with lactate as the outcome, BE as the primary covariate of interest and age, sex, and medical emergency type as confounders.
RESULTS: In our analysis population (n=312), lactate and BE levels were inversely correlated (Spearman's ρ, -0.75; p<0.001). From the adjusted multiple linear regression model (n=302), we estimated that a 1 mEq/L increase in BE levels was associated with an average change of -0.35 (95 % CI: -0.39, -0.30; p<0.001) mmol/L in lactate levels. Lactate levels were moderately useful for predicting mortality with notable variations across different emergency types.
CONCLUSIONS: Our study highlights a significant inverse association between lactate levels and BE in the prehospital setting, underscoring their importance in early assessment and prognosis in emergency care. Additionally, the findings from our secondary aims emphasize the value of lactate in diagnosing acid-base disorders and predicting patient outcomes. Recognizing the nuances in lactate physiology is essential for effective prehospital care in various emergency scenarios.
INTRODUCTION: Partial nephrectomy is currently the preferred treatment option for T1a renal cell carcinomas (RCC), with nephron-sparing techniques, including microwave ablation, becoming more common in select patients. Primary aims are to document outcomes of microwave ablation for T1a RCCs in an Australian tertiary centre to add to the evidence for its safety and efficacy.
METHODS: The prospectively maintained Sir Charles Gairdner Hospital Interventional Radiology database was retrospectively searched for all Renal Microwave ablations completed between June 2012 and February 2022. This database and a combination of hospital programmes including Agfa Impax PACS, Bossnet digital medical record and iSoft Clinical Manager were used to extract the relevant data which was anonymized and entered into an Excel spreadsheet for analysis.
RESULTS: Forty-eight patients underwent microwave ablation for 50 tumours. Of these, there were two local and two distant recurrences. A fifth patient had metastases on presentation. Higher local recurrence rates were associated with larger tumour size (P = 0.043). Tumour proximity to the collecting system <4 mm was associated with higher rates of complications (P = 0.020). RENAL scores did not show statistically significant correlation with complications (P = 0.092) or local or distant recurrence. Notably, the study follow-up time was longer than many comparative studies (mean = 2796, ~7.66 years censoring for death and mean = 832 days, ~2.28 years not censoring for death).
CONCLUSION: Consistent with the literature, this study further demonstrates that microwave ablation is a safe and efficacious option for treatment of T1a RCC.
A total of 527 patients with chronic hepatitis B induced liver failure were recruited from May 2005 to June 2009 from our department. The diagnoses of chronic hepatitis B and liver failure were based on previously described criteria. All patients received the same medical treatments (reducibility glutathione, glycyrrhizin, ademetionine, polyene phosphatidylcholine, alprostadil, and human serum albumin). Informed consent was obtained before study. Among these patients, 53 received transplantation with autologous MMSCs. The day of surgery served as the first day of observation. And 105 patients with matched age, gender and some biochemical indexes (ALT, ALB, TBIL, PT and MELD ) were served as controls.
To provide an occupational therapy support device and method and an artificial intelligence learning device and method for acquiring data useful to execute an occupational therapy without depending upon an evaluator.SOLUTION: An occupational therapy support device includes an input data reception part, an estimation part, and an estimation data output part. The input data reception part receives input data including sleep data of an object person 11 of occupational therapy evaluation and including no basic data of the object person. The estimation part inputs the received input data to a learned artificial intelligence 23, and causes the artificial intelligence to estimate daily life activity data of the object person and physical function data of the object person. The estimation data output part outputs the data estimated by the artificial intelligence. The sleep data is data of an item about sleep including information on at least one of a heart beat/respiration/body motion. The daily life activity data is data of an item about daily life activities to be evaluated in a plurality of stages about at least one of evaluation items determined by a functional independence degree evaluation method.SELECTED DRAWING: Figure 2
Two infusions of low dose Ketamine combined with trauma-focused psychotherapy. Low dose ketamine infusion will take place on day 2 and day 4, of the psychotherapy intervention. A physician will oversee and administer the ketamine infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following ketamine infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady state of ketamine infusion of 0.2 mg/kg for 40 minutes.
All consecutive patients with an implantable cardioverter defibrillator (ICD) due to non-ischemic cardiomyopathy and LVEF \<35% presenting for ICD check-up to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
Participants will receive a single dose of 300 milligram (mg) inclisiran administered by SC injection on Day 1. Normal renal function is defined as estimated creatinine clearance (CrCl) of ≥90 milliliter (mL)/minute (min).
The goal of this single center prospective observational study is to determine the effect of chemotherapy on (the change in) vital parameters. The main question it aims to answer are: Can changes in vital parameters be measured by using a Fitbit in patients with cancer while undergoing chemotherapy. Participants will be asked to wear a Fitbit for the first two cycles of chemotherapy to evaluate the changes in vital parameters. Patients will start measuring in the week prior to the first cycle of chemotherapy, target is at least 4 to 7 days before initiation of chemotherapy. Patients were the Fitbit as much as possible, during day and night. Patients continuously carry the Fitbit during the first 3 months of systemic treatment, which tracks their vital signs. At the starting day of the next cycle of chemotherapy patients will have an appointment with one of the researchers to evaluate the use of the Fitbit. Furthermore, it will be checked if a patient has returned to their baseline vital signs.
Use of an extract of Ravenala for antiaging action of skin, mucous membranes or its annexes, is claimed. Independent claims are included for: (1) a composition comprising the extract and carrier; and (2) a device, which is in a form comprising a pot, pump bottle, wiper, mask, transdermal device, patch, spray, capsule, food supplement, comprising the extract or the composition. ACTIVITY : Nootropic; Dermatological. MECHANISM OF ACTION : Collagen synthesis stimulator. The ability of Ravenala extract (at concentration of 10 -> 7>) to stimulate collagen synthesis was tested in normal human dermal fibroblasts. The result showed that the extract exhibited the percentage of collagen synthesis of 37% after 48 hours.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety of Rolvedon was evaluated in Study 1 and Study 2 [see Clinical Studies (14)]. Patients with early-stage breast cancer received Rolvedon 13.2 mg by subcutaneous injection (n=314) or pegfilgrastim 6 mg by subcutaneous injection (n=326) on Day 2 of each cycle after docetaxel 75 mg/m2 and cyclophosphamide 600 mg/m2 (TC) chemotherapy.

Among patients receiving Rolvedon, a total of 272 patients received four 21-day treatment cycles. The most common adverse reactions (≥20%) were fatigue, nausea, diarrhea, bone pain, headache, pyrexia, anemia, rash, myalgia, arthralgia, and back pain. Table 1 summarizes the adverse reactions that occurred in Studies 1 and 2.

Permanent discontinuation due to an adverse reaction occurred in 4% of patients who received Rolvedon. The adverse reaction requiring permanent discontinuation in 3 patients who received Rolvedon was rash.
Comfilcon A contact lenses worn bilaterally (in both eyes) for approximately 30 days, with a scheduled visit at approximately Day 15 of the wear period. Lenses will be removed nightly for cleaning and disinfection with CLEAR CARE contact lens solution.